{"name": "Osteoporosis","source": "American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. 2016, Endocrine Practice. pp. 3,6,14,15. \nFound at https:\/\/drive.google.com\/file\/d\/1sK-0Bw_4DAyfO3nPqXX-1ScZ5VsSNNtL\/view?usp=sharing","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Diagnose Osteoporosis","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Detailed history and physical exam","description": "A detailed history, physical exam, and [..] should be included in the initial evaluation for osteoporosis (Grade B; BEL 2).","node_type": "task_node","workflow_state": "completedState","decisional_state": "chosenState"},{"name": "FRAX assessment","description": "[..] and clinical fracture risk assessment with the Fracture Risk Assessment Tool (FRAX\u00AE) should be included in the initial evaluation for osteoporosis (Grade B; BEL 2).","node_type": "task_node","workflow_state": "completedState","decisional_state": "chosenState"},{"name": "BMD assessment","description": "R3. Consider bone mineral density (BMD) testing based on clinical fracture risk profile (Grade B; BEL 2).\nR4. When BMD is measured, axial dual-energy X-ray absorptiometry (DXA) measurement (spine and hip) should be used (Grade B; BEL 2).","node_type": "task_node","workflow_state": "completedState","decisional_state": "chosenState"},{"name": "Diagnosis outcome","node_type": "decision_node","workflow_state": "startedState","decisional_state": "chosenState","after": "Diagnose Osteoporosis","children": [{"name": "Halt","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "notChosenState","condition": "negative"},{"name": "Osteoporosis treatment","node_type": "task_node","workflow_state": "activeState","decisional_state": "chosenState","condition": "positive","children": [{"name": "Decide drug treatment","description": "Patients with high risk for future fractures (>=20%) should be given medications to reduce the risk.","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"name": "Drugs to reduce fractures","description": "R23. Approved agents with efficacy to reduce hip, non-vertebral, and spine fractures including alendronate, risedronate, zoledronic acid, and denosumab are appropriate as initial therapy for most patients at high risk of fracture (Grade A; BEL 1).","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "high fracture risk"}]},{"name": "Suspend contributing factors","description": "If the patient is taking a drug (e.g., PPI) known to be a contributing factor to osteoporosis, consider stopping that drug.","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState"}]}]}]}]}